Skip to main content
Veterinary Medicines

MONZAL 100 mg/ml SOLUCION INYECTABLE

Authorised
  • Vetrabutine hydrochloride

Product identification

Medicine name:
MONZAL 100 mg/ml SOLUCION INYECTABLE
Active substance:
  • Vetrabutine hydrochloride
Target species:
  • Pig (female)
  • Dog (bitch)
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Vetrabutine hydrochloride
    100.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig (female)
      • Meat and offal
        28
        day
    • Dog (bitch)
  • Subcutaneous use
    • Pig (female)
      • Meat and offal
        28
        day
    • Dog (bitch)
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG02CA90
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Labiana Life Sciences S.A.
Responsible authority:
  • (AEMPS)
Authorisation number:
  • 656 ESP
Date of authorisation status change:

Documents

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 28/11/2023

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 28/11/2023

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 28/11/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."